Russell Szmulewitz, MD, is an expert in the treatment and management of prostate, bladder, kidney, and testicular cancers. His clinical focus is on the treatment of patients with advanced prostate cancer, with particular expertise in the use of leading-edge hormonal, targeted, and immunotherapies. Dr. Szmulewitz works in close collaboration with urologists, radiation oncologists, and geriatricians who also specialize in the care of prostate cancer patients.

His research bridges the clinic and laboratory and focuses on the process of prostate cancer metastasis. In particular, his research attempts to better define the steps involved in metastatic progression and evolution to castration resistance in prostate cancer, with the goal of developing targeted therapies for these processes. In addition, Dr. Szmulewitz’s laboratory is developing strategies to isolate and interrogate circulating tumor cells (CTC) to better understand the biology of prostate cancer, and eventually personalize care based on this individualized biology.

Dr. Szmulewitz is particularly involved in therapeutic development for prostate cancer. He is an investigator on many clinical research trials focusing on immunotherapy, anti-angiogentic, and other novel targeted therapies for prostate cancer.

Year Started Practice
2009

Board Certifications
Internal Medicine
Medical Oncology

Medical School
Pritzker School of Medicine, University of Chicago

Internship and Residency
New York Medical Center

Fellowship
The University of Chicago Medicine

Memberships
American Association for Cancer Research
American College of Physicians
American Society of Clinical Oncology
Metastasis Research Society

Language Spoken
English